Primary engraftment failure in patients with malignant hematopathy underging autologus hematopoietic

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户:talenthers312
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background and Objection Autologus hematopoietic stem cell transplantation (auto-HSCT) has now been widely used in treatment of malignant hematopathy,some solid tumor,and autoimmune diseases and so on.Engraftment failure (EF) is a severe complication after auto-HSCT,and is occurring in 2 %to 9.5 %of patients.
其他文献
Method (1)According to cytogenetic marker、genetic test and clinical therapeutic efficacy,totally 113 patients with newly diagnosed AML(non-APL) hospitalised in our department from august 2011 to Janua
会议
Objective Sorafenib is a novel orally available inhibitor of multiple kinases.It has been used in relapsed and refractory FMS-like tyrosine kinase (FLT)-3 positive AML in recent years with favorable o
会议
Amyloid precusor protein (APP) has been reported to be highly expressed in AML1/ETO positive acute myeloid leukemia (AML1/ETO+ AML),and we found it express even higher in those with extramedullary inf
会议
Background The influence of cytomegalovirus (CMV) infection on the outcome of hematopoietic stem cell transplantation (HSCT) remains uncertain.This meta-analysis was conducted to assess the associatio
会议
Background Mesenchymal stem cells (MSCs) have been considered as a promising strategy for the prevention and treatment of acute graft-versus-host disease (aGVHD),but the mechanism of MSCs ameliorating
会议
The purpose of this study is to evaluate the effect of epithelial progenitor cells (EPC) infusion on the development of hepatic veno-occlusive disease (HVOD) following allogeneic hematopoietic stem ce
会议
The purpose of this study is to evaluate and compare the effect of total body irradiation (TBI) with busulfan/cyclophosphamide (BU/CY) as conditioning regimen on the development of hepatic veno-occlus
会议
Background and Aims Mesenchymal stromal cells (MSCs) are emerging as a promising therapeutic tool for the treatment of graft-versus-host disease (GVHD).Some studies have indicated that the inflammator
会议
Administration of standard-dose prednisone and high-dose dexamethasone remains as the first-line treatment for immune thrombocytopenia (ITP) and rituximab is recommended as a second-line treatment.We
会议
Objective To investigate the underlying mechanism of chronic graft-versus-host disease(cGVHD) and the role of specific mTOR inhibitor in the prevention of cGVHD in murine model.Methods DBA/2(H-2d)→BAL
会议